Guided Therapeutics (GTHP) Share-based Compensation (2011 - 2025)
Guided Therapeutics (GTHP) reported Share-based Compensation of $25000.0 for Q4 2025, up 292.31% on a YoY basis from $6372.5 in Q4 2024, and up 65.37% sequentially from $15118.0 in Q3 2025.
Guided Therapeutics (GTHP) Share-based Compensation (2011 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 15 years of Share-based Compensation data on file, last reported at $25000.0 in Q4 2025.
- For the quarter ending Q4 2025, Share-based Compensation rose 292.31% year-over-year to $25000.0; the trailing twelve-month figure through Dec 2025 stood at $27137.0 (up 38.62% YoY), and the FY2025 full-year result was $377000.0, up 214.17% from the prior year.
- Share-based Compensation improved to $25000.0 in Q4 2025, from $15118.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.1 million in Q2 2023 to a low of -$54000.0 in Q4 2023.
- A 5-year average of $130116.6 and a median of $44000.0 in 2022 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 2443.18% in 2023, while the deepest fall reached 114.06% in 2023.
- Tracing GTHP's Share-based Compensation over 5 years: stood at $71000.0 in 2021, then surged by 440.85% to $384000.0 in 2022, then slumped by 114.06% to -$54000.0 in 2023, then surged by 75.93% to -$13000.0 in 2024, then jumped by 292.31% to $25000.0 in 2025.
- Business Quant data shows GTHP's Share-based Compensation at $25000.0 in Q4 2025, $15118.0 in Q3 2025, and $131435.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 317.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 139.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 95.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 83.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 45.40 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 35.80 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 35.12 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 35.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | 25,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Sep 30, 2025 | 15,118.00 |
| Sep 30, 2025 | 15,118.00 |
| Jun 30, 2025 | 131,435.00 |
| Jun 30, 2025 | 131,435.00 |
| Mar 31, 2025 | 19.00 |
| Mar 31, 2025 | 19.00 |
| Dec 31, 2024 | -13,000.00 |
| Dec 31, 2024 | -13,000.00 |
| Sep 30, 2024 | 16,145.00 |
| Sep 30, 2024 | 16,145.00 |
| Jun 30, 2024 | 16,401.00 |
| Jun 30, 2024 | 16,401.00 |
| Mar 31, 2024 | 30.00 |
| Mar 31, 2024 | 30.00 |
| Dec 31, 2023 | -54,000.00 |
| Dec 31, 2023 | -54,000.00 |
| Sep 30, 2023 | 17,183.00 |
| Sep 30, 2023 | 17,183.00 |